Tan C D, Sokos G G, Pidwell D J, Smedira N G, Gonzalez-Stawinski G V, Taylor D O, Starling R C, Rodriguez E R
Department of Anatomic Pathology, Cleveland Clinic, Cleveland, OH, USA.
Am J Transplant. 2009 Sep;9(9):2075-84. doi: 10.1111/j.1600-6143.2009.02748.x. Epub 2009 Jul 16.
Antibody-mediated rejection (AMR) is an immunopathologic process in which activation of complement often results in allograft injury. This study correlates C4d and C3d with HLA serology and graft function as diagnostic criteria for AMR. Immunofluorescence staining for C4d and C3d was performed on 1511 biopsies from 330 patients as part of routine diagnostic work-up of rejection. Donor-specific antibodies were detected in 95% of those with C4d+C3d+ biopsies versus 35% in the C4d+C3d- group (p = 0.002). Allograft dysfunction was present in 84% in the C4d+ C3d+ group versus 5% in the C4d+C3d- group (p < 0.0001). Combined C4d and C3d positivity had a sensitivity of 100% and specificity of 99% for the pathologic diagnosis of AMR and a mortality of 37%. Since activation of complement does not always result in allograft dysfunction, we correlated the expression pattern of the complement regulators CD55 and CD59 in patients with and without complement deposition. The proportion of patients with CD55 and/or CD59 staining was highest in C4d+C3d- patients without allograft dysfunction (p = 0.03). We conclude that a panel of C4d and C3d is diagnostically more useful than C4d alone in the evaluation of AMR. CD55 and CD59 may play a protective role in patients with evidence of complement activation.
抗体介导的排斥反应(AMR)是一种免疫病理过程,其中补体激活常导致同种异体移植物损伤。本研究将C4d和C3d与HLA血清学及移植物功能相关联,作为AMR的诊断标准。作为排斥反应常规诊断检查的一部分,对330例患者的1511份活检组织进行了C4d和C3d的免疫荧光染色。在C4d + C3d +活检的患者中,95%检测到供体特异性抗体,而在C4d + C3d -组中这一比例为35%(p = 0.002)。C4d + C3d +组中84%出现同种异体移植物功能障碍,而C4d + C3d -组中这一比例为5%(p < 0.0001)。C4d和C3d联合阳性对AMR病理诊断的敏感性为100%,特异性为99%,死亡率为37%。由于补体激活并不总是导致同种异体移植物功能障碍,我们比较了有和没有补体沉积患者中补体调节蛋白CD55和CD59的表达模式。在没有同种异体移植物功能障碍的C4d + C3d -患者中,CD55和/或CD59染色的患者比例最高(p = 0.03)。我们得出结论,在评估AMR时,C4d和C3d联合检测比单独检测C4d在诊断上更有用。CD55和CD59可能在有补体激活证据的患者中发挥保护作用。